We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+7.34%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.2B
AUM Growth
-$238M
(-17%)
Cap. Flow
-$147M
Cap. Flow
% of AUM
-12.32%
Top 10 Holdings %
Top 10 Hldgs %
60.4%
Holding
78
New
16
Increased
22
Reduced
29
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inspire Medical Systems
INSP
|
+$23.6M |
| 2 |
HCA Healthcare
HCA
|
+$14.7M |
| 3 |
Bio-Techne
TECH
|
+$12.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$11.9M |
| 5 |
Krystal Biotech
KRYS
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$42.8M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$36.3M |
| 3 |
GSK
GSK
|
+$30.5M |
| 4 |
Natera
NTRA
|
+$20.7M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$17.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.99% |
| 2 | Miscellaneous | 20.84% |
| 3 | Communication Services | 0.66% |
| 4 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Invesco QQQ Trust
QQQ
$489B
| $129M | 10.81% |
350,000
-100,000
| -22% | -$33.7M |
|
|
2
Natera
NTRA
$47B
| $117M | 9.82% |
2,413,787
-405,983
| -14% | -$20.7M |
|
|
3
GSK
GSK
$102B
| $104M | 8.68% |
2,881,012
-850,487
| -23% | -$30.5M |
|
4
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
| $102M | 8.52% |
230,000
-180,000
| -44% | -$75.5M |
|
|
5
Teva Pharmaceuticals
TEVA
$42.5B
| $57.7M | 4.83% |
7,668,044
+1,473,472
| +24% | +$11.9M |
|
6
United Therapeutics
UTHR
$22.1B
| $57.5M | 4.81% |
260,398
+38,291
| +17% | +$8.48M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $48.9M | 4.09% |
475,310
-343,814
| -42% | -$36.3M |
|
8
Syndax Pharmaceuticals
SNDX
$1.74B
| $45.8M | 3.83% |
2,189,732
-19,325
| -0.9% | -$402K |
|
9
Community Health Systems
CYH
$413M
| $32M | 2.68% |
7,277,856
-1,804,449
| -20% | -$7.68M |
|
|
10
Bio-Techne
TECH
$11.3B
| $28M | 2.34% |
342,637
+153,978
| +82% | +$12.4M |
|
11
Vera Therapeutics
VERA
$2.46B
| $27.9M | 2.34% |
1,740,951
-47,578
| -3% | -$430K |
|
|
12
Inspire Medical Systems
INSP
$1.78B
| $26.8M | 2.24% |
+82,445
| New | +$23.6M |
|
13
Celldex Therapeutics
CLDX
$3.07B
| $26.7M | 2.23% |
785,740
+96,064
| +14% | +$3.24M |
|
14
Danaher
DHR
$152B
| $24.8M | 2.08% |
116,573
-51,144
| -30% | -$10.8M |
|
|
15
HCA Healthcare
HCA
$90.5B
| $24.5M | 2.05% |
80,725
+52,816
| +189% | +$14.7M |
|
16
Illumina
ILMN
$32.6B
| $23.3M | 1.94% |
127,525
-47,787
| -27% | -$9.67M |
|
17
Icon
ICLR
$13.1B
| $17.9M | 1.5% |
71,726
-5,062
| -7% | -$1.07M |
|
|
18
BioCryst Pharmaceuticals
BCRX
$2.51B
| $16.7M | 1.4% |
2,372,113
-2,148,611
| -48% | -$17.2M |
|
19
Amneal Pharmaceuticals
AMRX
$6.11B
| $16.3M | 1.36% |
5,265,251
+82,205
| +2% | +$175K |
|
|
CTLT
20
DELISTED
CATALENT, INC.
CTLT
| $15.5M | 1.29% |
356,875
-216,734
| -38% | -$9.52M |
|
21
Seres Therapeutics
MCRB
$51.3M
| $14.7M | 1.23% |
153,838
+27,005
| +21% | +$2.94M |
|
|
22
Krystal Biotech
KRYS
$10.4B
| $12.5M | 1.05% |
+106,465
| New | +$10.9M |
|
|
AMRN
23
Amarin Corp
AMRN
$295M
| $12.5M | 1.04% |
525,105
-205,533
| -28% | -$5.28M |
|
|
ABCM
24
DELISTED
Abcam PLC
ABCM
| $12.2M | 1.02% |
+499,394
| New | +$8.62M |
|
25
PUT
AMN Healthcare
AMN
$1.34B
| $10.4M | 0.87% |
95,000
+55,000
| +138% | +$5.21M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Eversept Partners held 78 positions worth $1.2B, down 17% from $1.43B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Eversept Partners withdrew a net $147M in Q2 2023, closing 7 positions and reducing 29 holdings. Its most notable exit was Biogen, an estimated $42.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Eversept Partners opened a new position in Inspire Medical Systems worth $26.8M.
- Eversept Partners's largest Q2 2023 buy was Inspire Medical Systems: 82,445 shares worth $26.8M.
- Eversept Partners added most to HCA Healthcare in Q2 2023, an estimated $14.7M increase.
- Eversept Partners's biggest Q2 2023 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $36.3M.
- Eversept Partners fully exited Biogen in Q2 2023, selling an estimated $42.8M.
- Eversept Partners's ten largest holdings make up 60% of its $1.2B portfolio in Q2 2023.
- Eversept Partners opened 16 new positions and closed 7 in Q2 2023.
- Eversept Partners's portfolio value fell 17% quarter-over-quarter to $1.2B.
Based on Eversept Partners's 13F filing for Q2 2023, filed 14 Aug 2023.